Galderma’s First-In-Class Biologic Chases Eczema Spoils
Galderma’s novel biologic is heading for Phase III studies in moderate-to-severe atopic dermatitis as the race to join Dupixent in an expanding market hots up.
You may also be interested in...
The VC firm known for its new company formation efforts will launch 10-12 biopharma, device and diagnostic ventures with its fifth fund. Also, EpimAb raises a $74m series B round, three more drug developers join the IPO queue and Amicus leads recent follow-on offerings.
Almirall has re-affirmed its dermatology emphasis by entering a lebrikizumab option and license pact with Dermira for treating eczema in Europe.
Galderma has acquired most global rights to a first-in-class antibody from Chugai that will both strengthen the Swiss skin specialist's atopic dermatitis portfolio and provide its first biologic therapy.